BioPoint Inc

BioPoint Inc. is a US-based Life Sciences consulting firm focused in the areas of Drug Safety.

is a US based life sciences consulting organization focused in the areas of Drug Safety, Health Economic

10/29/2025

Lilly is growing its direct-to-consumer services, allowing patients to pick up online orders at Walmart pharmacies. https://www.biopharmadive.com/news/lilly-walmart-zepbound-retail-pickup-obesity/804108/

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest move by the company to expand its direct-to-consumer services.

10/28/2025

GSK is betting on the future of RNA-based medicine, committing $85 million upfront and potentially $745 million overall for a new therapy targeting chronic lung conditions. The company believes this innovative approach could benefit a wide range of sufferers. https://www.biopharmadive.com/news/gsk-empirico-copd-sirna-drug-deal/804012/

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a "broad spectrum" of people with the chronic lung condition.

10/27/2025

Lynkuet's clearance offers a novel, non-hormonal treatment for hot flashes, providing a new choice for patients and creating a competitive landscape with Astellas Pharma's Veozah. https://www.biopharmadive.com/news/bayer-fda-approval-lynkuet-menopause-vasomotor-symptoms/753979/

Clearance of Lynkuet provides a new alternative to hormone-based treatment for hot flashes and sets up a market battle with Astellas Pharma’s Veozah.

10/24/2025

Vanqua Bio's preclinical drug aims to reduce inflammation by blocking the activity of C5aR1, a protein involved in the body's immune response. https://www.biopharmadive.com/news/biogen-vanqua-deal-rights-licensing-drug-immune-C5aR1/803770/

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

10/23/2025

While the drug did not promote weight loss, analysts highlighted its significant positive impact on cardiovascular and inflammation markers. https://www.biopharmadive.com/news/ventyx-nlrp3-cardiovascular-obesity-drug-results/803582/

The drug’s effects on cardiovascular and inflammation markers outshined its failure to spur weight loss, analysts wrote.

10/20/2025

For breast cancer patients unable to receive immunotherapy, Datroway showed improved survival outcomes in a study presented at the European Society for Medical Oncology. https://www.biopharmadive.com/news/astrazeneca-daiichis-datroway-excels-in-hard-to-treat-breast-cancer/803225/

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer patients for whom immunotherapy is not an option.

10/16/2025

Addressing the unmet need in hair loss treatment, Pelage Pharmaceuticals, backed by GV and Arch Venture Partners...this unique formulation aims to stimulate dormant hair follicle stem cells, potentially reversing hair thinning. https://www.biopharmadive.com/news/pelage-hair-loss-therapy-drug-fundraise-series-b-arch-gv/802857/

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to activate dormant hair follicle stem cells.

10/14/2025

A significant private funding round is backing the global expansion of trials for a novel obesity treatment, an injectable medication that recently demonstrated positive results in late-stage testing within China. https://www.biopharmadive.com/news/kailera-Series-B-bain-obesity-drugs-hengrui-GLP-1-GIP/802689/

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.

10/09/2025

The transaction represents the third acquisition, initiated since May, of a therapeutic agent with the potential to reverse hepatic fibrosis in patients diagnosed with metabolic dysfunction-associated steatohepatitis. https://www.biopharmadive.com/news/novo-akero-acquire-MASH-drug-efruxifermin-fgf21-89bio/802465/

The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis.

10/08/2025

Zenas has struck a deal with InnoCare Pharma, potentially worth $2 billion, gaining rights to a late-stage BTK inhibitor for multiple sclerosis and two earlier-stage immune therapies. https://www.biopharmadive.com/news/zenas-innocare-china-deal-immune-drugs-multiple-sclerosis-btk/802323/

A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple sclerosis and two other immune medicines in earlier development.

10/07/2025

The pharmaceutical landscape saw significant shifts this week. A settlement could protect the market exclusivity of the top-selling HIV drug until 2036. Elsewhere, AstraZeneca's acquisition strategy yielded positive results, and Stoke Therapeutics named a new CEO, a veteran of Vertex Pharmaceuticals. https://www.biopharmadive.com/news/gilead-delays-arrival-of-biktarvy-copycats-cdc-updates-vaccine-schedule/802011/

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug acquisition paid more dividends and a Vertex veteran became Stoke’s full-time CEO.

10/06/2025

This research could lead to Datroway becoming a new standard of care for some triple-negative tumors, potentially surpassing chemotherapy. It already has established approvals for other breast and lung cancer types. https://www.biopharmadive.com/news/astrazeneca-daiichi-datroway-triple-negative-breast-cancer-results/802007/

The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing clearances in other breast and lung malignancies.

Address

13 Centennial Drive Ste. 1
Peabody, MA
01960

Website

http://www.biopointinc.com/

Alerts

Be the first to know and let us send you an email when BioPoint Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BioPoint Inc:

Shortcuts

Want your practice to be the top-listed Clinic in Peabody?